| Literature DB >> 29261657 |
James Heaf1, Aivars Petersons2, Baiba Vernere2, Maija Heiro3, Johan V Povlsen4, Anette Bagger Sørensen4, Mai Rosenberg5, Niels Løkkegaard6, Fabiola Alonso-Garcia7, Jan Dominik Kampmann7, Naomi Clyne8, Else Randers9, Olof Heimburger10, Bengt Lindholm10.
Abstract
INTRODUCTION: The incidence of unplanned dialysis initiation (DI) with consequent increased comorbidity, mortality and reduced modality choice remains high, but the optimal timing of dialysis initiation (DI) remains controversial, and there is a lack of studies of specific reasons for DI. We investigated why and when physicians prescribe dialysis and hypothesized that physician motivation for DI is an independent factor which may have clinical consequences.Entities:
Mesh:
Year: 2017 PMID: 29261657 PMCID: PMC5737975 DOI: 10.1371/journal.pone.0188309
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Clinical and laboratory characteristics at the time of dialysis initiation in 446 patients with CKD5.
| Mean ±SD | Median (IQ range) | |
|---|---|---|
| Age (years) | 64.2 ±14,7 | 67.0 (55–75) |
| Females (n; %) | 170; 38.0 | |
| Height (cm) | 172 ±10 | 172 (165–179) |
| Body weight (kg) | 79.4 ±21.7 | 75 (65–90) |
| Body weight non-diabetics | 76.7 ±18.6 | 74 (64–87) |
| Body weight diabetics | 88.6 ±28.2 | 83.5 (70–101) |
| Body mass index (kg/m2) | 26.5 ±6.1 | 25.0 (22.5–29.3) |
| BMI non-diabetics | 26.0 ±5.6 | 24.7 (22.3–28.4) |
| BMI diabetics | 28.3 ±7.1 | 27.5 (23.2–30.9) |
| Number of comorbidities | 1.39 ±1.4 | 1 (0–2) |
| Creatinine (μM) | 689 ±303 | 631 (508–797) |
| Hemoglobin (mM) | 6.3 ±1.1 | 6.2 (5.6–6.9) |
| Potassium (mM) | 4.5 ±0.8 | 4.4 (3.9–4.9) |
| Urea (mM) | 33.7 ±11.9 | 31.8 (25.6–39.7) |
| Bicarbonate (mM) | 20.9 ±5.2 | 21.0 (17.6–24.8) |
| Albumin (mM) | 33.8 ±6.7 | 34 (29–39) |
| C-reactive protein (mg/l) | 38 ±59 | 10 (3–49) |
| Ionized calcium (mM) | 1.14 ±0.12 | 1.14 (1.07–1.21) |
| Phosphate (mM) | 1.99 ±0.56 | 1.95 (1.60–2.31) |
| eGFR (ml/min/1.73 m2) | 7.2 ±3.4 | 6.7 (5.0–8.7) |
| eGFR 3 months previously | 14.0 ±13.6 | 10.1 (8.5–13.5) |
| Change in eGFR (ml/min/1.73 m2/yr) | 10.3 (3.7–21.6) | |
| Myocardial infarction | 11.2 | |
| Cardiac failure | 16.1 | |
| Cardiac disease | 23.8 | |
| Cerebrovascular disease | 12.6 | |
| Peripheral vascular disease | 13.0 | |
| Diabetes | 25.6 | |
| Cancer | 13.7 | |
| Pulmonary disease | 11.2 | |
| Hepatic disease | 4.3 | |
| Psychiatric disease | 4.7 | |
| Previous transplant | 2.9 | |
| No comorbidity | 19.7 |
*Not stated; a minority of patients had extreme values.
Primary, secondary and additional other reasons, clinical and biochemical, for prescribing chronic dialysis initiation in 446 patients.
| Primary | Secondary | Other | Total | |||||
|---|---|---|---|---|---|---|---|---|
| No. | Percent | No. | Percent | No. | Percent | No. | Percent | |
| Pulmonary edema | 46 | 10.3 | 2 | 0.2 | 2 | 0.4 | 50 | 11.2 |
| Dyspnea | 16 | 3.6 | 4 | 0.9 | 24 | 5.4 | 44 | 9.9 |
| Hypertension | 4 | 0.9 | 5 | 1.1 | 27 | 6.1 | 36 | 8.1 |
| Pericarditis | 2 | 0.4 | 1 | 0.2 | 4 | 0.9 | 7 | 1.6 |
| Edema | 37 | 8.3 | 16 | 3.6 | 40 | 9.0 | 92 | 21.1 |
| Cardiac symptoms | 4 | 0.9 | 8 | 1.8 | 13 | 2.9 | 25 | 5.6 |
| Fatigue | 97 | 21,7 | 43 | 9.6 | 80 | 17.9 | 220 | 49.3 |
| Anorexia | 9 | 2.0 | 25 | 5.6 | 62 | 13.9 | 96 | 21.5 |
| Nausea | 41 | 9.2 | 23 | 5.2 | 41 | 9.2 | 105 | 23.5 |
| Cachexia/weight loss | 9 | 1.8 | 10 | 2.2 | 36 | 8.1 | 55 | 12.3 |
| Pruritis | 9 | 2.0 | 13 | 2.9 | 52 | 11.7 | 74 | 16.6 |
| Insomnia | 0 | 0 | 3 | 0.7 | 22 | 4.9 | 25 | 5.6 |
| Depression | 0 | 0 | 2 | 0.4 | 17 | 3.8 | 19 | 4.3 |
| Diarrhea | 0 | 0 | 0 | 0 | 5 | 1.1 | 5 | 1.1 |
| Taste disturbances | 1 | 0.2 | 0 | 0 | 10 | 2.2 | 11 | 2.5 |
| Cerebral symptoms | 1 | 0.2 | 0 | 0 | 4 | 0.9 | 5 | 1.1 |
| Social | 0 | 0 | 0 | 0 | 5 | 1.1 | 5 | 1.1 |
| Practical | 3 | 0.7 | 1 | 0.2 | 1 | 0.2 | 5 | 1.1 |
| Other | 1 | 0.2 | 0 | 0 | 9 | 2.0 | 10 | 2.2 |
| 280 | 62.7 | 156 | 35.0 | 234 | 52.5 | 373 | 83.6 | |
| 102 | 22.9 | 178 | 40.0 | |||||
| High creatinine | 30 | 6.7 | 26 | 5.8 | 101 | 22.6 | 157 | 35.2 |
| Low eGFR | 55 | 12.3 | 32 | 7.2 | 99 | 22.2 | 186 | 41.7 |
| High creatinine or low eGFR | 85 | 19.1 | 265 | 69.4 | ||||
| Falling eGFR | 17 | 3.8 | 34 | 7.6 | 62 | 13.9 | 113 | 25.3 |
| High urea | 30 | 6.7 | 37 | 8.3 | 73 | 16.4 | 140 | 31.4 |
| High potassium | 23 | 5.2 | 13 | 2.9 | 25 | 5.6 | 60 | 13.5 |
| Acidosis | 10 | 2.2 | 17 | 3.8 | 47 | 10.5 | 74 | 16.6 |
| Low calcium | 0 | 0 | 2 | 0.4 | 13 | 2.9 | 15 | 3.4 |
| High calcium | 0 | 0 | 0 | 0 | 2 | 0.4 | 2 | 0.4 |
| High phosphate | 1 | 0.2 | 0 | 0 | 49 | 11.0 | 50 | 11.2 |
| 166 | 37.2 | 161 | 36.1 | 228 | 51.1 | 371 | 83.1 | |
Fig 1Primary reasons for chronic dialysis initiation (DI) in 446 patients with CKD5.
Clinical reasons accounted for 63% and biochemical reasons for 37% of all DI. The 12 most common motivations accounted for 91% of all DI prescriptions, “fatigue” being most common (22%) among clinical motivations, and “low GFR” (13%) most common among DI based on biochemical grounds.
Fig 2Uremic symptoms at dialysis initiation (DI) in 446 patients with CKD5 in percent.
Symptoms were present in 83% of patients, the most common being fatigue (44%), nausea (24%) and anorexia (22%). Black bars: primary symptoms; hatched bars: secondary or other symptoms.
The stated primary reason for dialysis initiation in 446 patients and characteristics of prescribing physicians (n = 52) who agreed to provide their details.
Number and percent (in brackets).
| eGFR | Primary reason | Clinical reasons | Biochemical reasons | 1° Life-threatening reason | |||||
|---|---|---|---|---|---|---|---|---|---|
| ml/min/1.73 m2 | Clinical | Biochemical | None | Some | None | Some | Yes | No | |
| <50 | 7.8 ±.9 | 71 (51.4) | 67 | 30 (21.7) | 108 | 13 (8.8) | 125 | 38 (27.5) | 100 |
| >49 | 7.3 ±3.3 | 139 (71.6) | 55 | 21 (10.8) | 173 | 47 (24.2) | 147 | 35 (18.4) | 154 |
| Male | 7.2 ±3.5 | 134 (62.6) | 80 | 32 (14.9) | 182 | 43 (20.1) | 171 | 35 (16.4) | 179 |
| Female | 8.0 ±3.6 | 76 (64.4) | 42 | 19 (16.1) | 99 | 17 (14.4) | 101 | 38 (32.2) | 80 |
| <23 yrs | 7.9 ±3.9 | 71 (51.8) | 66 | 30 (21.9) | 107 | 13 (9.5) | 124 | 38 (27.7) | 99 |
| >22 yrs | 7.2 ±3.3 | 139 (71.3) | 56 | 21 (10.7) | 174 | 47 (24.1) | 148 | 35 (18.0) | 160 |
| None | 8.0 ±4.8 | 31 (66.0) | 16 | 2 (4.2) | 45 | 6 (12.7) | 41 | 18 (38.3) | 29 |
| <14 yrs | 7.6 ±3.5 | 64 (51.2) | 61 | 34 (27.2) | 91 | 16 (12.8) | 109 | 32 (25.6) | 93 |
| >13 yrs | 7.3 ±3.1 | 115 (71.8) | 45 | 15 (9.3) | 145 | 38 (23.8) | 122 | 23 (14.4) | 137 |
*:p<0.05;
**:p<0.01;
***:p<0.001;
a: significance values compared to specialists;
b:compared to specialists with more experience
Biochemical primary reasons for dialysis initiation in 446 patients as stated by prescribing physicians (n = 84) and how these reasons relate to the corresponding measurements in presence or absence of stating these reasons as a cause to start dialysis.
| Term | Present | Absent | P | ||||
|---|---|---|---|---|---|---|---|
| No. | Mean ±SD | Median (IQ range) | No. | Mean ±SD | Median (IQ range) | ||
| High creatinine (μM) | 30 | 781 ±333 | 707 (545–947) | 282 | 675 ±343 | 635 (495–790) | (0.06) |
| (corresponding eGFR (ml/min/1.73 m2)) | 6.5 ±3.3 | 5.6 (4.3–8.4) | 7.2 ±3.5 | 6.6 (5.0–8.7) | NS | ||
| Low eGFR (ml/min/1.73 m2) | 51 | 6.1 ±2.1 | 5.9 (4.8–7.4) | 251 | 7.6 ±3,7 | 6.9 (5.1–9.4) | <0.01 |
| (corresponding creatinine (μM)) | 719 ±258 | 669 (576–825) | 678 ±317 | 627 (575–825) | NS | ||
| Falling eGFR (ml/min/1.73 m2/yr | 11 | 9.2 (2.4–47.6) | 238 | 11.7 (4.3–22.5) | NS | ||
| High urea (mM) | 30 | 42.2 ±15.6 | 39.6 (33.0–49.2 | 298 | 32.0 ±11.2 | 29.5 (24.9–38.5) | <0.001 |
| High potassium (mM) | 22 | 5.7 ±1.3 | 6.0 (4.5–6.5) | 364 | 4.3 ±0.7 | 4.3 (3.9–4.8) | <0.001 |
| Acidosis (mM) | 10 | 16.0 ±8.7 | 13.6 (10–19) | 305 | 21.7 ±4.9 | 22 (18–25) | <0.001 |
| Low calcium | 15 | 0.96 ±0.11 | 0.96 (0.86–1.02) | 402 | 1.14 ±0.12 | 1.15 (1.08–1.22) | <0.001 |
| High phosphate | 44 | 2.17 ±0.57 | 2.04 (1.83–2.33) | 367 | 1.97 ±0.55 | 1.92 (1.56–2.30) | <0.05 |
*primary, secondary and other reasons combined.
Biochemical correlates to primary reasons, ranked according to eGFR.
| eGFR | BMI | Albumin | Bicarbonate | C-reactive protein | |
|---|---|---|---|---|---|
| Cachexia | 9.8 ±5.7 | 21,3 ±3.3 | 34,8 ±3.3 | 21,9 ±6.4 | 3 (1–3) |
| Pericarditis | 8.9 ±3.8 | 28,1 ±1.8 | 31,0 ±5.7 | 24,0 ±8.5 | 158 (-) |
| Anorexia | 8.4 ±1.8 | 27,7 ±6.2 | 36,8 ±7.1 | 22,2 ±3.3 | 7 (3–17) |
| Pulmonary stasis | 8.2 ±4.8 | 27,6 ±7.6 | 32,0 ±6.5 | 20,5 ±5.7 | 38 (9–91) |
| Falling eGFR | 8.1 ±3.5 | 23,2 ±3.7 | 34,8 ±7.1 | 19,4 ±3.4 | 22 (4–72) |
| Itching | 7.9 ±3.4 | 24,8 ±4.5 | 34,1 ±9.8 | 21,6 ±2.6 | 24 (5–37) |
| Fatigue | 7.9 ±3.5 | 26,8 ±5.7 | 35,0 ±6.2 | 21,6 ±4.9 | 5 (3–25) |
| Cardiac symptoms | 7.5 ±4.8 | 25,4 ±4.4 | 35,7 ±4.9 | 19,0 ±2.6 | 20 (1–139) |
| High potassium | 7.3 ±3.3 | 24,9 ±7.9 | 32,4 ±7.5 | 18,6 ±4.9 | 25 (4–75) |
| High urea | 7.2 ±3.5 | 24,6 ±4.0 | 33,5 ±5.4 | 20,8 ±5.7 | 14 (3–60) |
| Nausea | 7.0 ±3.3 | 24,2 ±5.0 | 32,9 ±8.0 | 20,8 ±4.6 | 3 (3–33) |
| High creatinine | 6.5 ±3.3 | 25,0 ±4.4 | 35,1 ±6.4 | 20,3 ±5.8 | 12 (10–146) |
| Dyspnea | 6.3 ±2.3 | 29,0 ±6.7 | 31,2 ±7.1 | 19,9 ±6.6 | 65 (10–146) |
| Hypertension | 6.3 ±2.6 | 31,0 ±9.4 | 36,3 ±1.5 | 19,0 ±2.0 | 9 (2–24) |
| Edema | 6.1 ±2.0 | 25,9 ±5.2 | 30,1 ±6.1 | 20,3 ±5.5 | 19 (3–86) |
| Low eGFR | 6.1 ±2.1 | 25,8 ±4.7 | 36,5 ±6.2 | 22,4 ±4.1 | 5 (3–20) |
| Acidosis | 4.6 ±2.3 | 27,6 ±6.1 | 31,1 ±7.9 | 16,0 ±8.7 | 29 (3–69) |
| Primary Clinical | 7.5 ±3.6 | 26.3 ±5.9 | 33.4 ±6.7 | 21.1 ±5.1 | 10 (3–54) |
| Primary Biochemical | 6.6 ±3.0 | 25.2 ±5.1 | 34.7 ±6.6 | 20.6 ±5.4 | 11 (3–44) |
| Life-threatening | 7.3 ±4.0 | 26.2 ±5.9 | 31.9 ±6.8 | 19.5 ±6.1 | 37 (5–91) |
| Not life-threatening | 7.4 ±3.3 | 25.7 ±5.4 | 35.1 ±6.6 | 22.0 ±4.7 | 6 (3–30) |
| No clinical | 7.1 ±3.1 | 26.0 ±5.7 | 34.9 ±7.2 | 20.6 ±5.4 | 9 (3–53) |
| Some clinical | 7.2 ±3.5 | 25.8 ±5.7 | 33.6 ±6.6 | 21.0 ±5.1 | 11 (3–49) |
| No biochemical | 8.2 ±3.6 | 25.0 ±5.6 | 34.2 ±6.7 | 20.5 ±5.2 | 12 (3–86) |
| Some biochemical | 7.0 ±3.3 | 26.0 ±5.7 | 33.7 ±6.7 | 21.0 ±5.2 | 9 (3–45) |
| All | 7.2 ±3.4 | 25.8 ±5.7 | 33.8 ±6.7 | 20.9 ±5.2 | 10 (3–49) |
aexcluding patients with type 2 DM;
b: Median (IQ range);
**:p<0.01;
***:p<0.001
Correlations to renal diagnosis, patient sex and patient age.
No. patients (%).
| eGFR | Primary reason | Clinical reasons | Biochemical reasons | 1° Life-threatening reason | |||||
|---|---|---|---|---|---|---|---|---|---|
| ml/min/1.73 m2 | Clinical | Biochemical | None | Some | None | Some | Yes | No | |
| Diabetic | 7.8 ±3.2 | 81(77.1) | 24 | 11 (10.5 | 94 | 19 (18.1) | 86 | 27 (25.7) | 78 |
| Polycystic | 7.6 ±2.5 | 17 (51.5) | 16 | 4 (12.1) | 29 | 7 (21.2) | 26 | 8 (24.2) | 25 |
| Unknown | 7.1 ±2.7 | 31 (59.6) | 21 | 9 (17.3) | 43 | 9 (17.3) | 43 | 12 (23.1) | 40 |
| Chronic interstitial | 7.1 ±3.5 | 26 (61.9) | 16 | 9 (21.3) | 33 | 7 (16.7) | 35 | 10 (23.8) | 32 |
| Other | 7.1 ±5.7 | 27 (56.3) | 21 | 9 (18.8) | 39 | 5 (10.4) | 43 | 15 (31.2) | 33 |
| Hypertesnive | 7.0 ±2.8 | 48 (60.0) | 32 | 16 (20.0) | 64 | 15 (18.8) | 65 | 15 (18.7) | 65 |
| Glomerulonephritis | 6.7 ±3.2 | 50 (58.1) | 36 | 14 (16.3) | 72 | 13 (15.1) | 73 | 15 (17.4) | 71 |
| Male | 7.4 ±3.5 | 171 (62.0) | 105 | 42 (15.2) | 234 | 49 (17.8) | 227 | 70 (25.3) | 206 |
| Female | 7.0 ±3.2 | 109 (64.5) | 60 | 30 (17.8) | 139 | 26 (15,4) | 143 | 32 (18.9) | 137 |
| <60 | 7.1 ±3.8 | 94 (63.1) | 55 | 21 (14.1) | 128 | 17 (11.4) | 132 | 26 (17.5) | 123 |
| 60–71 | 7.4 ±3.3 | 91 (64.5) | 50 | 23 (16.3) | 118 | 31 (22.0) | 110 | 34 (24.1) | 107 |
| >71 | 7.1 ±3.2 | 91 (61.1) | 58 | 26 (17.5) | 123 | 27 (18.1) | 122 | 42 (28.1) | 107 |
*:p<0.05;
***:p<0.001;
a: see text;
b: versus other diagnoses;
c: versus other age groups.
Proportion of clinical causes as reason for dialysis initiation and selected measurements in relation to number of comorbidities.
| No. comorbidities | No. | Primary clinical cause | eGFR | BMI | Albumin | Bicarbonate | C-reactive protein |
|---|---|---|---|---|---|---|---|
| 0 | 137 | 58 | 6,4 ±2.6 | 26,0 ±5.5 | 35,6 ±6.8 | 20,5 ±5.0 | 4 (3–26) |
| 1 | 148 | 59 | 7,2 ±3.7 | 25,6 ±5.8 | 33,6 ±6.6 | 21,3 ±5.3 | 8 (3–35) |
| 2 | 71 | 65 | 7,0 ±2.4 | 26,6 ±6.2 | 33,3 ±7.0 | 21,2 ±5.2 | 20 (3–71) |
| 3 | 47 | 72 | 8,1 ±3.8 | 25,3 ±5.8 | 33,2 ±5.7 | 19,5 ±5.3 | 18 (9–76) |
| >3 | 43 | 79 | 8,7 ±4.7 | 25,3 ±4.3 | 31,0 ±6.2 | 21,4 ±5.0 | 37 (9–73) |
aexcluding patients with type 2 DM;
**:p<0.01;
***:p<0.001